Table 1.

Background characteristics of the patients (PPS population)

Parameter	Value for group
	Combined (n = 37)	300-mg (n = 18)	600-mg (n = 19)
Gender [no. (%)]
Male	15 (40.5)	7 (38.9)	8 (42.1)
Female	22 (59.5)	11 (61.1)	11 (57.9)
Age (yr)
Mean	50.9	51.5	50.4
SD	16.2	16.2	16.7
No. (%) ≤65	28 (75.7)	14 (77.8)	14 (73.7)
No. (%) >65	9 (24.3)	4 (22.2)	5 (26.3)
Poorly controlled diabetes [no. (%)]
Yes	4 (10.8)	2 (11.1)	2 (10.5)
No	33 (89.2)	16 (88.9)	17 (89.5)
Current drug therapy for a respiratory tract disease [no. (%)]
Yes	29 (78.4)	15 (83.3)	14 (73.7)
No	8 (21.6)	3 (16.7)	5 (26.3)
Current use of a drug that suppresses immune function [no. (%)]
Yes	9 (24.3)	5 (27.8)	4 (21.1)
No	28 (75.7)	13 (72.2)	15 (78.9)
Time of influenza onset [no. (%)]
0–12 h	2 (5.4)	1 (5.6)	1 (5.3)
12–24 h	15 (40.5)	8 (44.4)	7 (36.8)
24–36 h	10 (27.0)	5 (27.8)	5 (26.3)
36–48 h	10 (27.0)	4 (22.2)	6 (31.6)
Influenza vaccinationa [no. (%)]
Yes	19 (51.4)	7 (38.9)	12 (63.2)
No	18 (48.6)	11 (61.1)	7 (36.8)
Influenza virus subtype [no. (%)]
A/H1	16 (43.2)	7 (38.9)	9 (47.4)
A/H3	13 (35.1)	4 (22.2)	9 (47.4)
A/H5	0 (0.0)	0 (0.0)	0 (0.0)
A/-	1 (2.7)	1 (5.6)	0 (0.0)
B	3 (8.1)	3 (16.7)	0 (0.0)
Unknown	4 (10.8)	3 (16.7)	1 (5.3)
IC50 of peramivir
n	34	15	19
Mean	11.68	12.74	10.84
SD	10.48	10.52	10.66
Minimum	0.72	0.72	0.74
Median	9.97	19.20	3.75
Maximum	25.02	24.13	25.02
Administration [no. (%)]
1 day	10 (27.0)	7 (38.9)	3 (15.8)
2 days	23 (62.2)	9 (50.0)	14 (73.7)
3 days	2 (5.4)	1 (5.6)	1 (5.3)
4 days	1 (2.7)	0 (0.0)	1 (5.3)
5 days	1 (2.7)	1 (5.6)	0 (0.0)
Mean no. of days of administration (mean dose in mg)	1.91 (884)	1.83 (550)	2.0 (1200)

^aPatients had trivalent inactivated influenza vaccination between autumn 2008 and enrollment in the study.